Publications (25)

2023

  1. Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection

    Open Forum Infectious Diseases, Vol. 10, Núm. 2

  2. Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS

    Journal of medical economics, Vol. 26, Núm. 1, pp. 463-472

2022

  1. The Characteristics and Functionalities of Mobile Apps Aimed at Patients Diagnosed With Immune-Mediated Inflammatory Diseases: Systematic App Search

    Journal of Medical Internet Research, Vol. 24, Núm. 3

  2. Information and Communication Technologies in Patients With Immune-Mediated Inflammatory Diseases: Cross-sectional Survey

    Journal of medical Internet research, Vol. 24, Núm. 9, pp. e37445

  3. Implementation and evaluation of a home pharmaceutical care model through Telepharmacy

    Farmacia Hospitalaria, Vol. 46, pp. 36-46

  4. Evaluation of the hospital care quality perceived by patients with immune-mediated inflammatory diseases from the pharmacy service. SACVINFA study

    Journal of Clinical Pharmacy and Therapeutics, Vol. 47, Núm. 12, pp. 2020-2029

  5. Dolutegravir-Based Dual Therapies in HIV Pretreated Patients: A Real-Life Study in Madrid

    Annals of Pharmacotherapy, Vol. 56, Núm. 4, pp. 401-411

  6. Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare

    Frontiers in Immunology, Vol. 13

  7. Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience

    Revista Espanola de Quimioterapia, Vol. 35, Núm. 3, pp. 279-283

2021

  1. Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain

    Expert Review of Clinical Pharmacology, Vol. 14, Núm. 2, pp. 249-260

  2. COVID-19 in hospitalised patients in Spain: a cohort study in Madrid

    International Journal of Antimicrobial Agents, Vol. 57, Núm. 2

2020

  1. Topical Administration of Amphotericin B as an Effective Adjuvant Treatment for a Deep Fungal Infection of Diabetic Foot Injury

    American journal of therapeutics, Vol. 27, Núm. 6, pp. e670-e671

  2. Hepatitis C virus infection and the role of a pharmaceutical care program

    American Journal of Health-System Pharmacy, Vol. 77, Núm. 6, pp. 479-486

  3. Etiology and Prognosis of Pneumonia in Patients with Solid Tumors: A Prospective Cohort of Hospitalized Cases

    Oncologist, Vol. 25, Núm. 5, pp. e861-e869

  4. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients

    Annals of Pharmacotherapy, Vol. 54, Núm. 7, pp. 633-643

  5. A retrospective cohort of invasive fusariosis in the era of antimould prophylaxis

    Medical Mycology, Vol. 58, Núm. 3, pp. 300-309

2019

  1. A case-control study of real-life experience with ceftolozane-tazobactam in patients with hematologic malignancy and pseudomonas aeruginosa infection

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 2

2018

  1. Sofosbuvir/ledipasvir as treatment of hepatitis C virus genotype 5 infection: Two case reports

    Medicina Clinica

  2. Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study

    Expert Opinion on Drug Safety, Vol. 17, Núm. 3, pp. 235-241

  3. Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients

    Annals of Pharmacotherapy, Vol. 52, Núm. 1, pp. 11-18